Subscribe
shutterstock_1886551888_emily_frost
2 November 2023GenericsMarisa Woutersen

Setback for Alvogen in approval bid for IBS generic

District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
Purdue hits Alvogen with ANDA lawsuit
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
Purdue hits Alvogen with ANDA lawsuit
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.

More on this story

Americas
US judge invalidates Pernix patents in Alvogen clash
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
Purdue hits Alvogen with ANDA lawsuit
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB